Fundraising FoxBioverge — Full Portfolio
8 tracked investments · listed companies and verified rows first
Alto Neuroscience is a clinical-stage biopharmaceutical company developing biology-driven medicines for neuropsychiatric conditions, using measurements of brain biology to predict clinical response and identify patients likely to benefit from its drug candidates.
BiotechDigital HealthMental HealthMountain View, US
Amit Etkin(Founder)inAdam Savitz(Executive Officer)inMichael Hanley(Executive Officer)Nicholas Smith(Chief Financial Officer and Chief Business Officer)inAaron Weaver(Director)Po Yu (Jeff) Chen(Director)
Co-investorsAble PartnersAlpha Wave GlobalGaingelsInVivium CapitalK2 HealthVenturesKorify Capital+12 more
__Twitter.png)
Aspen Neuroscience develops iPSC-derived autologous cell therapies for neurological diseases, with a lead product (ANPD001) in Phase 1/2a clinical trials for Parkinson's disease.
BiotechDeep TechDigital HealthMedical DevicesSan Diego, US
Andrés Bratt-Leal(Co-Founder and Senior Vice President, Research & Development)inANDRÉS BRATT-LEAL, Ph.D.(Co-Founder; Senior Vice President, Research & Development)Damien McDevitt(President and Chief Executive Officer)inDAMIEN MCDEVITT, Ph.D.(President and Chief Executive Officer)
Co-investorsARCH Venture PartnersLifeforce CapitalOrbiMedDomain AssociatesEDB InvestmentsSection 32+10 more
Developing microscale robots to deliver therapies locally to targeted brain disease areas.
Co-investorsAlumni VenturesBlue Ivy VenturesBold Capital PartnersCompoundDeep InsightDolby Family Ventures+9 more
EnClear Therapies is a bio/med-tech company developing the EnTrega CSF platform, focused on cerebrospinal fluid-related therapies.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Anthony DePasqua(Executive Officer, Director)inKevin Kalish(COO)inMarcie Glicksman(VP Biology)inWilliam Gormley(CMO)Jason Camm(Director)Kasper Roet(Director)in
Co-investors20/20 HealthCare Partners LLCDolby Family VenturesFlucas VenturesTachyon VenturesVU Venture PartnersAmgen Ventures+1 more
Modulo is a biotech company focused on the neuroimmune system, developing treatments for brain and central nervous system disorders.
AI & Machine LearningBiotechDeep TechLos Altos, US
Mike Horowitz(CEO & Co-founder)Justin Ichida(Co-founder)inScott Patterson(CTO & Co-founder)inJoe Wagner(Chief Development Officer)
BoardAlda Leu Dennis(Director)inNicholas Saccomano(Director)
Co-investorsCantos VenturesGaingelsHAWKTAILInitialized CapitalLifespan Vision VenturesMana Ventures+3 more
Notable Labs operates an automated laboratory that tests combinations of existing drugs against individual patients' blood cancer cells to identify effective treatment options for patients whose cancers have become resistant to standard therapies.
BiotechHealthtechMedical DevicesSan Francisco, US
Matthew De Silva(CEO)inPete Quinzio(Founder)inConnor Warnock(Senior Engineer)Van Duesterberg(Science Consultant)Omid Karkouti(Vice President of Business Development)Scott Patterson(Vice President of Engineering)
Co-investors11.2 CapitalAlumni VenturesBuilders VCFundersClubGaingelsHemisphere Ventures LLC+30 more
Ochre Bio develops RNA therapeutics and drug discovery platforms targeting liver disease, combining proprietary human liver datasets with AI-driven causal prediction and human tissue validation models.
AI & Machine LearningBiotechHealthtechMedical DevicesLondon, GB
Quin Wills(CSO)inJack O'Meara(Founder)in
BoardChinwe UkomaduElaine SullivanEliot ForsterJack Castle
Co-investorsBackedBeast VenturesCoastCapEntrepreneur FirstExpaGaingels+18 more
Volumetric Biotechnologies, acquired by 3D Systems in 2021, develops bioprinting materials and vascularized human tissue constructs.
BiotechDeep TechHealthtechMedical DevicesHouston, US
Jordan Miller(President)inBagrat Grigoryan(COO)in
Co-investorsGaingelsGoAhead VenturesHarmonix FundHelios CapitalJoyance PartnersJude Gomila+21 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.